At what pace is the covid-19 drug associated apis market growing, and what is its estimated value?
The COVID-19 drug associated apis market size has grown strongly in recent years. It will grow from $6.75 billion in 2024 to $7.14 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to the rising prevalence of COVID-19, increasing awareness of COVID-19 treatment options, expanding access to COVID-19 drugs, growing demand for COVID-19 drugs for prophylaxis, government initiatives, and supply chain resilience.
The COVID-19 drug associated apis market size is expected to see strong growth in the next few years. It will grow to $9.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the development of new COVID-19 drug modalities, increasing clinical trials for COVID-19 drugs, rising demand for COVID-19 vaccines, emerging variants, vaccination campaigns, and pandemic preparedness. Major trends in the forecast period include customized API production, diversification of API sources, advanced manufacturing technologies, digitalization and data analytics, sustainability and green chemistry.
Get Your Free Sample of The Global COVID-19 Drug Associated APIs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3248&type=smp
What are the top drivers to the rising demand in the covid-19 drug associated apis market?
High demand for antiretrovirals, antimalarials, sedatives, bronchodilators, and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients (APIs) are the biologically active components used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. FDA has approved Airsupra (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years of age and older. Favipiravir, which is used to treat influenza in Japan, has also shown a positive effect on COVID-19 patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for the COVID-19 drug-associated APIs market over the forecast period.
How is the covid-19 drug associated apis market segmented?
The COVID-19 drug associated apis market covered in this report is segmented –
1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class
2) By Synthesis Type: Synthetic, Biotech
3) By Business Mode: Captive API, Merchant API
Subsegments:
1) By Antimalarials: Hydroxychloroquine, Chloroquine
2) By Bronchodilators: Beta-Agonists, Anticholinergics
3) By Antibiotics: Macrolides, Tetracyclines
4) By Antivirals: Remdesivir, Favipiravir, Lopinavir Or Ritonavir
5) By Other Drug Classes: Corticosteroids, Immunomodulators
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report
Who are the top competitors in the covid-19 drug associated apis market?
Major companies operating in the COVID-19 drug associated apis market include Dr. Reddy’s Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd., Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.
How will industry trends affect the trajectory of the covid-19 drug associated apis market?
Key players operating in the pharmaceutical industry that manufacture COVID-19 drug-associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of COVID-19 cases across the globe. For instance, in October 2023, Merck & Co., Inc., a US-based pharmaceutical company, with a recent partnership with the Heavy Water Board in India, hopes to tap into the deuterated raw compound industry, which is presently worth around $100 million and has the potential to rise to $1 billion over the next five to ten years. Merck seeks to support India’s chemical, pharmaceutical, and technical sectors by offering high-quality compounds for the manufacture of medicines, semiconductors, OLEDs, and electronics. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients.
How do regional factors impact the covid-19 drug associated apis market, and which region is the largest contributor?
North America was the largest region in the COVID-19 drug-associated APIs market in 2024. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated APIs market share during the forecast period. The regions covered in the COVID-19 drug associated APIs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The COVID-19 Drug Associated APIs Market Report 2025 Offer?
The covid-19 drug associated apis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
COVID-19 drug-associated APIs refer to the active pharmaceutical components that are employed in the production of COVID-19 medications. Chemicals called active pharmaceutical components serve as the foundation for pharmaceutical drugs and medicines and are responsible for pharmacological activity in the human body.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3248
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
